SG Americas Securities LLC Has $211,000 Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

SG Americas Securities LLC lifted its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 89.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,145 shares of the company’s stock after acquiring an additional 19,478 shares during the period. SG Americas Securities LLC’s holdings in Adaptive Biotechnologies were worth $211,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Manchester Capital Management LLC acquired a new stake in shares of Adaptive Biotechnologies in the first quarter worth $32,000. MQS Management LLC acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $36,000. Rothschild Investment LLC acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $36,000. Nisa Investment Advisors LLC grew its stake in shares of Adaptive Biotechnologies by 769.6% in the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock worth $48,000 after acquiring an additional 11,852 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth $49,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analysts Set New Price Targets

ADPT has been the topic of several research analyst reports. BTIG Research raised their price objective on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. lifted their price target on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Adaptive Biotechnologies Price Performance

ADPT opened at $4.70 on Wednesday. Adaptive Biotechnologies Co. has a fifty-two week low of $2.28 and a fifty-two week high of $5.80. The firm’s fifty day moving average price is $4.70 and its two-hundred day moving average price is $3.94. The company has a market capitalization of $692.63 million, a P/E ratio of -3.15 and a beta of 1.44.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. The company had revenue of $43.19 million during the quarter, compared to analysts’ expectations of $38.63 million. Adaptive Biotechnologies had a negative return on equity of 60.99% and a negative net margin of 126.49%. The business’s revenue was down 11.7% on a year-over-year basis. During the same period last year, the business earned ($0.33) earnings per share. On average, equities research analysts expect that Adaptive Biotechnologies Co. will post -1.19 EPS for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.